Published in Onco Targets Ther on May 06, 2016
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne) (2016) 0.75
Photoinduced Conversion of Antimelanoma Agent Dabrafenib to a Novel Fluorescent BRAF(V600E) Inhibitor. ACS Med Chem Lett (2016) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (2010) 10.61
MAP kinase signalling pathways in cancer. Oncogene (2007) 8.52
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol (2014) 4.60
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (2015) 3.13
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res (2012) 2.46
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2010) 2.23
Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol (2012) 2.23
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res (2000) 1.70
BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res (2011) 1.47
Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol (2012) 1.32
Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med (2012) 1.28
Lack of BRAF mutations in uveal melanoma. Cancer Res (2003) 1.27
Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol (2012) 1.27
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol (2016) 1.27
Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer (2011) 1.21
Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother (2002) 1.15
Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther (2010) 1.04
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer (1980) 1.02
Paradoxical oncogenesis: are all BRAF inhibitors equal? Pigment Cell Melanoma Res (2013) 0.97
Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol (2013) 0.87
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann Oncol (2014) 0.87
Treatment of melanoma brain metastases: a new paradigm. Cancer J (2012) 0.86
A case of vemurafenib-induced keratosis pilaris-like eruption. Dermatol Online J (2012) 0.86
High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib. Acta Derm Venereol (2014) 0.80
Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma. J Am Acad Dermatol (2014) 0.77
Pyogenic granuloma as a cutaneous adverse effect of vemurafenib. N Engl J Med (2014) 0.77
Lupus erythematosus-like skin eruption after vemurafenib therapy. J Am Acad Dermatol (2014) 0.76
Total Nevi, Atypical Nevi, and Melanoma Thickness: An Analysis of 566 Patients at 2 US Centers. JAMA Dermatol (2016) 1.44
Dermoscopy of primary cutaneous B-cell lymphoma (PCBCL). J Am Acad Dermatol (2016) 0.98
Recent advances in dermoscopy. F1000Res (2016) 0.98
Validity and Reliability of Dermoscopic Criteria Used to Differentiate Nevi From Melanoma: A Web-Based International Dermoscopy Society Study. JAMA Dermatol (2016) 0.94
The dermoscopic variability of dermatofibromas. J Am Acad Dermatol (2015) 0.83
Ex vivo fluorescence confocal microscopy in conjunction with Mohs micrographic surgery for cutaneous squamous cell carcinoma. J Am Acad Dermatol (2015) 0.79
Ex Vivo Fluorescence Confocal Microscopy of Eccrine Syringomatous Carcinoma: A Report of 2 Cases. JAMA Dermatol (2015) 0.77
Dermoscopy of dermatofibrosarcoma protuberans on black skin. J Am Acad Dermatol (2016) 0.76
Dermoscopic hemorrhagic dots: an early predictor of response of psoriasis to biologic agents. Dermatol Pract Concept (2016) 0.75
Superficial angiomyxoma of the skin. Dermatol Pract Concept (2016) 0.75
Dermoscopy and Reflectance Confocal Microscopy for Monitoring the Treatment of Actinic Keratosis with Ingenol Mebutate Gel: Report of Two Cases. Dermatol Ther (Heidelb) (2016) 0.75
Scabies escaping detection until dermoscopy was applied. Dermatol Pract Concept (2017) 0.75
Dermoscopy of cutaneous lymphangioma circumscriptum. Dermatol Pract Concept (2017) 0.75
Pigmented eccrine poroma: dermoscopic and confocal features. Dermatol Pract Concept (2016) 0.75
Non-follicular milky globules-dermoscopy saves the day. Dermatol Pract Concept (2017) 0.75
Atypical case of lichen planus recognized by dermoscopy. Dermatol Pract Concept (2016) 0.75
Dermoscopy as an evolving tool to assess vitiligo activity. J Am Acad Dermatol (2017) 0.75
Dermoscopy of lymphangioma circumscriptum: A morphological study of 45 cases. Australas J Dermatol (2017) 0.75
A new direction for Dermatology Practical & Conceptual. Dermatol Pract Concept (2017) 0.75
Vascular structures in dermal nevi: a reappraisal. Int J Dermatol (2016) 0.75
Acral melanoma. J Am Acad Dermatol (2017) 0.75
Orthovoltage radiotherapy for nonmelanoma skin cancer (NMSC): Comparison between 2 different schedules. J Am Acad Dermatol (2015) 0.75
When a melanoma is uncovered by a tattoo. Int J Dermatol (2015) 0.75
Performance of the "if in doubt, cut it out" rule for the management of nodular melanoma. Dermatol Pract Concept (2017) 0.75
Accuracy of dermatoscopy for the diagnosis of nonpigmented cancers of the skin. J Am Acad Dermatol (2017) 0.75
Dermoscopy pathology correlation in melanoma. J Dermatol (2017) 0.75
MELTUMP: how to manage these lesions in the clinical routine. G Ital Dermatol Venereol (2017) 0.75
Keratoacanthoma-like dermatofibroma: A dermoscopic challenge. J Am Acad Dermatol (2017) 0.75
Distribution of the dermatoscopic features of melanoma of trunk and extremities according to the anatomic sub-location. J Am Acad Dermatol (2020) 0.75
Dermatofibroma looks dermoscopically different on trunk versus extremities. G Ital Dermatol Venereol (2015) 0.75
Dermoscopy in vitiligo: diagnosis and beyond. Int J Dermatol (2017) 0.75
Dermoscopy of Kyrle disease. J Am Acad Dermatol (2016) 0.75
Melanoma: clinical and dermoscopic diagnosis. G Ital Dermatol Venereol (2017) 0.75
Dermoscopy of Grover disease. J Am Acad Dermatol (2017) 0.75
Dermoscopy of Porokeratosis of Mibelli. Indian Dermatol Online J (2017) 0.75
Clinical Indications for Use of Reflectance Confocal Microscopy for Skin Cancer Diagnosis. JAMA Dermatol (2016) 0.75
5-point checklist for skin cancer detection in primary care. G Ital Dermatol Venereol (2017) 0.75
Dermoscopy in the diagnosis and management of basal cell carcinoma. Future Oncol (2015) 0.75
Dermoscopy of clear cell acanthoma. J Am Acad Dermatol (2015) 0.75
Cutaneous metastasis of renal carcinoma. J Am Acad Dermatol (2015) 0.75
Collision tumors: A diagnostic challenge. J Am Acad Dermatol (2016) 0.75